Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,194.00
Bid: 12,194.00
Ask: 12,196.00
Change: 98.00 (0.81%)
Spread: 2.00 (0.016%)
Open: 12,150.00
High: 12,286.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Pound Keeps Lid On FTSE 100 As BoE Boosts Support

Thu, 05th Nov 2020 09:24

(Alliance News) - Stock prices in London were in the green early on Thursday, as investors took heart from the Bank of England boosting quantitative easing in the hopes of easing pressure on the UK's Covid-19 hit economy.

The UK central bank on Thursday kept interest rates on hold, as expected, but upped QE by GBP150 billion, a bit more than anticipated, taking its total stock of UK government bond purchases to GBP875 billion.

The pound was quoted at USD1.3015 early on Thursday, improved from USD1.2977 on Wednesday evening.

"Stocks on the FTSE are being supported after the Bank of England announced that it will pump an additional GBP150 billion into the economy as the UK goes into lockdown," said Gain Capital analyst Fiona Cincotta.

She added: "The pound breathed a sigh of relief; early morning rumours had suggested that the BoE was going to cut rates which had sent the pound sharply lower."

The FTSE 100 index of London large-cap stocks was up 8.04 points, or 0.1% at 5,891.30. The blue-chip index had risen as much as 0.6% to 5,916.27 earlier on Thursday morning before giving back some of that gain.

The FTSE 250 rose 54.99 points, or 0.3%, at 17,851.07. The AIM All-Share was up 1.05 points, 0.1%, at 975.79.

The Cboe UK 100 index was up 0.1% at 584.79. The Cboe 250 was up 0.4% at 15,014.49. The Cboe Small Companies lost 0.2% at 9,607.24.

The CAC 40 stock index in Paris rose 0.9% in early trade on Wednesday, and Frankfurt's DAX 30 was up 1.1%.

The euro improved to USD1.1757, from USD1.1710 at the European market close on Wednesday.

The US presidential election remains undecided. Joe Biden has 264 electoral college votes versus Trump's 214, with 270 votes required to win. However, Trump has requested recounts in several states and threatens legal action.

"On paper this was the worst-case scenario, an undecided, contested Presidential election. The reality is that the market couldn't seem happier with the most likely outcome of a Democrat President, and Republican Senate," said Cincotta, adding: "This is because Joe Biden's tax [hikes] are unlikely to be passed by a Republican Senate. Gridlock in Capitol Hill on this occasion could be good news for stocks."

Versus the Japanese yen, the dollar was at JPY104.31, down from JPY104.49 at the London market close on Wednesday.

On the London Stock Exchange, AstraZeneca left annual guidance unchanged after posting a 3% third-quarter revenue hike. Its shares were up 0.2% in early trading.

Revenue in the quarter amounted to USD6.58 billion, taking revenue for the nine-month period to USD19.21 billion, 8% higher annually on a reported basis, or 10% at constant currency.

"We made encouraging headway in the quarter, despite the ongoing disruption from the COVID-19 pandemic. Highlights of the sales performance included further success in Oncology and an acceleration in the progress of Farxiga," Chief Executive Officer Pascal Soriot said.

Looking ahead, annual revenue is still expected to grow by a "high single-digit to a low double-digit percentage" at constant currency.

Peer Hikma rose 1.6%. The pharmaceutical firm hailed "positive momentum in the first half".

Its Injectables unit saw less demand for Covid-19 related products so far in the second half of the year, compared to the first, though it backed the unit to achieve revenue between USD950 million and USD980 million.

Hikma lifted guidance at its Generics arm, however, expecting revenue between USD720 million and USD740 million, up from the previous range of USD710 million and USD730 million.

"Following a strong first half, our Generics business continues to perform well, supported by a better than expected contribution from new launches and strong demand across our differentiated portfolio," Hikma explained.

Supermarket chain Sainsbury's sat towards the bottom of the FTSE 100, down 2.8%. It sunk to a GBP137 million interim pretax loss, from a GBP9 million profit a year earlier. The company was hit by a bruising GBP438 million in one-off costs.

Group sales, excluding VAT but including fuel, inched 1.1% lower to GBP14.93 billion from GGBP15.10 billion. Like-for-like sales excluding fuel jumped 6.9% annually, however.

"Sales during the first half were stronger than the base case assumptions we outlined in April, particularly at Argos, driving a strong underlying profit increase against a soft comparative base," the company said.

Commenting on the lockdown that has gone into effect on Thursday in England, which doesn't close grocery stores and limits competition from restaurants, Sainsbury's said: "We cannot fully predict the impact of COVID-19 and lockdown restrictions on retail sales and costs for the remainder of the second half of the year, but our current assumptions would result in full year group underlying profit before tax increasing by at least 5% year-on-year."

Looking further ahead, the company said it will close around 420 Argos standalone stores, reducing the standalone estate to just 100 by March 2024. However, it will open 150 more Argos stores in Sainsbury's supermarkets by the target date, as well as 150 to 200 more Argos collection points in supermarkets and convenience stores.

Sainsbury confirmed that as part of its cost-cutting plans, "around 3,500" jobs could be lost. This is higher than the 3,000 job cuts reported by UK media outlets ahead of Thursday's results announcement. "We will do everything possible to find alternative roles for our colleagues," Sainsbury's said.

Elsewhere among the blue-chips, Homeserve was up 4.7%, the best performer, after Credit Suisse resumed coverage of the emergency home repairs business with an Outperform rating.

Away from the large-caps, N Brown shares dropped 6.3%. The retailer's revenue fell 18% to GBP356.7 million, and its pretax profit dropped by a quarter to GBP14.1 million in the six months ended August 31, a period hit by Covid-19 lockdowns.

With more curbs to come in England, N Brown said it will bolster its coffers through a GBP100 million placing and open offer.

The company also plans to delist from the London Main Market and move to the junior AIM market.

N Brown said AIM is a more "appropriate environment" and better suited for a company of its size.

Gold was quoted at USD1,918.02 early on Thursday in London, up from USD1,901.50 late Wednesday.

A barrel of Brent fetched USD40.86, up from USD40.62.

The economic calendar on Thursday has a UK Markit construction PMI at 0930 GMT. Eurozone retail sales are due at 1000 GMT and the weekly US initial jobless claims are out at 1330 GMT.

In the US, the Federal Open Market Committee will conclude its two-day policy meeting on Thursday and announce its decision at 1900 GMT. This will be followed by a press conference with Fed Chair Jerome Powell at 1930 GMT.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.